Portrait of a Mature African American man.

Oncopeptides in focus

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

Oncopeptides’ vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

We are science driven, entrepreneurial, and committed to bringing innovation to patients with diseases where there is a clear unmet need.

Oncopeptides’ first drug Pepaxti has been granted full approval for treatment of adult patients with multiple myeloma in Europe.

Our first innovative drug is based on the Peptide Drug Conjugate (PDC) platform, and offers patients robust efficacy, reduces treatment burden and maintains quality of life.

Our pipeline includes other drug candidates built on the PDC platform as well as the Small Polypeptide based Killer Engagers (SPiKE) platform.

We have a values-driven culture and inclusive organization that welcomes people with diverse backgrounds and perspectives.

We are headquartered in Stockholm, Sweden, have 75 coworkers and a modern pre-clinical drug development facility in Solna, outside of Stockholm.

Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

Company news

See all the latest company news.

To the archive

Oncopeptides value words in the Oncopeptides logo

Culture & values

Oncopeptides is a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Oncopeptides has a values-driven culture and an inclusive organization that welcomes people with different backgrounds and perspectives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history


The full marketing authorization of Pepaxti in Europe is the foundation for Oncopeptides’ strategy and enables us to give patients with multiple myeloma access to an innovative drug, that may reduce treatment burden and improve quality of life.

In addition to European sales, Oncopeptides has identified a number of next step value drivers that will drive the company into the future: sales of Pepaxti outside of Europe and the company’s innovation pipeline.

Read more

Board of Directors

After the general meeting, the board of directors is the Company’s highest decision-making body.

Read more


Oncopeptides’ senior management consists of the Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Chief Scientific Officer, Chief Medical Officer, Director of Corporate Affairs and Head of Human Resources.

Read more

Corporate governance

Oncopeptides has a number of policy documents and manuals containing rules and recommendations meant to guide the company’s operations and its employees. Internal governance documents steer the work of the Board of Directors, the duties of the CEO and instructions for financial reporting.

Read more


Being a responsible, sustainable company is important to Oncopeptides. It permeates our business operations and our relationships with employees and stakeholders in the society at large.

Read more


We are a global biotech company striving to attract, retain and develop some of the most talented people in industry.

Read more